AK131
As of the edition of 20 October 2026, AK131 is a drug known only by a code name: in active development; acts on NT5E.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2024
- Kind
- Code name only
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NT5E | 5'-nucleotidase | P21589 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Akeso | Lead sponsor of trials | 2024 to now |